Ethinyl estradiol / norethindrone Pregnancy and Breastfeeding Warnings
Ethinyl estradiol / norethindrone is also known as: Alyacen 1/35, Balziva, Estrostep Fe, Generess Fe, Gildess Fe 1.5/30, Gildess Fe 1/20, Jinteli, Junel 1/20, Junel Fe 1.5/30, Junel Fe 1/20, Lo Loestrin Fe, Loestrin 1/20, Loestrin 24 Fe, Loestrin Fe 1.5/30, Lomedia 24 Fe, Microgestin 1.5/30, Microgestin 1/20, Microgestin Fe 1/20, Minastrin 24 Fe, Necon 1/35, Ortho-Novum 1/35, Ortho-Novum 7/7/7, Ovcon 35, Zenchent, femhrt
Ethinyl estradiol / norethindrone Pregnancy Warnings
Ethinyl estradiol-norethindrone has been assigned to pregnancy category X by the FDA. Animal studies have failed to reveal evidence of teratogenicity. Ethinyl estradiol-norethindrone is considered contraindicated during pregnancy.
Although some reports have suggested that oral contraceptive hormones may cause a variety of congenital malformations, recent studies (including a meta-analysis of prospective studies) have suggested that an association between oral contraceptive use and congenital malformations does not exist. Some progestins may cause masculinization of female infants. One case report has suggested that oral contraceptive hormones may cause choreoathetosis in infants exposed in utero. A recent case control study has suggested a weak association between use of older high dose contraceptives (particularly those containing 1.0 mg of ethynodiol diacetate) and the occurrence of congenital limb defects. However, the authors concluded that "this weak causal relationship was probable in the past when relatively high doses of contraceptive pills were used. This risk is apparently minimized by the use of new type (e.g., D-norgestrel) and lower dose of contraceptive pills".
Ethinyl estradiol / norethindrone Breastfeeding Warnings
Some studies have examined the effect of progestin-only contraceptives on breast-feeding. The extent to which such studies have bearing on oral contraceptive combinations is uncertain. Use of such formulations have not been associated with deleterious effects on breast-fed infants.
Both the estrogens and progestins occurring in commercially available oral formulations are excreted into human milk in very small amounts. The American Academy of Pediatrics considers use of oral contraceptive combinations to be compatible with breast-feeding despite rare reports of breast enlargement in the nursing infant and the possibility of a decrease in milk production and protein content. The manufacturer recommends that caution be used when administering ethinyl estradiol-norethindrone to nursing mothers.
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.